Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

ABSTRACT:

Background

The intractability of castration-resistant prostate cancer (CRPC) is exacerbated by tumour heterogeneity, including diverse alterations to the androgen receptor (AR) axis and AR-independent phenotypes. The availability of additional models encompassing this heterogeneity would facilitate the identification of more effective therapies for CRPC.

Objective

To discover therapeutic strategies by exploiting patient-derived models that exemplify the heterogeneity of CRPC.

Design, setting, and participants

Four new patient-derived xenografts (PDXs) were established from independent metastases of two patients and characterised using integrative genomics. A panel of rationally selected drugs was tested using an innovative ex vivo PDX culture system.

Intervention</

SUBMITTER: Lawrence MG 

PROVIDER: S-EPMC6351078 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature